Delta-8-THCM

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| IUPAC_name = (6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene

| image = Delta-8-THCM_structure.png

| width = 220

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| metabolism =

| excretion =

| CAS_number = 1451-20-3

| PubChem = 15114753

| ChemSpiderID = 19975471

| ChEMBL = 114082

| ChEBI =

| UNII =

| C=22 | H=32 | O=2

| smiles = CCCCCC1=CC2=C([C@@H]3CC(=CC[C@H]3C(O2)(C)C)C)C(=C1)OC

| StdInChI=1S/C22H32O2/c1-6-7-8-9-16-13-19(23-5)21-17-12-15(2)10-11-18(17)22(3,4)24-20(21)14-16/h10,13-14,17-18H,6-9,11-12H2,1-5H3/t17-,18-/m1/s1

| StdInChIKey = GRLARWXSTOXAGR-QZTJIDSGSA-N

}}

Delta-8-THCM (O-Methyl-Δ⁸-THC) is a chemical compound related to phytocannabinoids found in Cannabis. It has been sold as a designer drug, first identified in Sweden in June 2024.{{cite web | title = European Drug Report 2025 – Full Book | date = 6 June 2025 | url = https://www.euda.europa.eu/system/files/documents/2025-06/edr-2025-full-book-6.06.2025-en.pdf | publisher = European Union Drugs Agency (euda.europa.eu) }} However, it is a known compound which has been well established to almost entirely lack cannabinoid-like effects in mice, rats and monkeys,{{cite book | vauthors = Mechoulam R, Edery H | veditors = Mecoulam R | chapter = Structure-Activity Relationships in the Cannabinoid series. | title = Marijuana Chemistry, Pharmacology, Metabolism, and Clinical Effects | location = New York | pages = 101–136 | date = 1973 | publisher = Academic Press }}{{cite journal | vauthors = Compton DR, Prescott WR, Martin BR, Siegel C, Gordon PM, Razdan RK | title = Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol | journal = Journal of Medicinal Chemistry | volume = 34 | issue = 11 | pages = 3310–3316 | date = November 1991 | pmid = 1659638 | doi = 10.1021/jm00115a023 }} unlike the dimethylheptyl analogue L-759,633 which is a selective agonist for CB₂ and has antiinflammatory but not psychoactive effects.{{cite journal | vauthors = Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG | title = Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630 | journal = British Journal of Pharmacology | volume = 126 | issue = 3 | pages = 665–672 | date = February 1999 | pmid = 10188977 | pmc = 1565857 | doi = 10.1038/sj.bjp.0702351 | authorlink6 = Alexandros Makriyannis }}